Next 10 |
home / stock / stro / stro articles
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Sutro Biopharma, Inc. (NASDAQ:STRO) ("Sutro" or the "Comp...
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
Oppenheimer initiated coverage on Sutro Biopharma Inc (NASDAQ: STRO), representing around 200% potential upside. The analysts ...
Brunilda Shtylla, Chief Business Officer at Sutro Biopharma (NASDAQ:STRO), reported a large insider sell on August 29, according to a new SEC filin...
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
Brunilda Shtylla, Chief Business Officer at Sutro Biopharma (NASDAQ:STRO), reported a large insider sell on August 28, according to a new SEC filin...
News, Short Squeeze, Breakout and More Instantly...
2024-03-26 08:30:04 ET H.C. Wainwright analyst issues BUY recommendation for STRO on March 26, 2024 06:07AM ET. The previous analyst recommendation was Buy. STRO was trading at $3.27 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current...
- Sutro highlighted luveltamab tazevibulin (luvelta) in a January 2024 investor webcast, describing the broad opportunity to address unmet needs in multiple FolRα-expressing cancers - - Compelling anti-leukemic activity of luvelta in pediatric patients with relapsed/refractory CB...
Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant ovarian cancer patients, including addressing unmet need in patients with low-medium FolRα expression P...